Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering what drives profitability at a veterinary roll-up? Investors exploring Inspire Veterinary Partners SEC filings usually start with questions like, “Where can I see Inspire Veterinary Partners quarterly earnings report 10-Q filing?� or “How do I track Inspire Veterinary Partners insider trading Form 4 transactions in real time?� This page answers those needs by collecting every IVP disclosure the moment it hits EDGAR and layering Stock Titan’s AI summaries on top, so locating same-clinic revenue trends or new-hospital purchase prices no longer requires hours of scrolling.
Use the annual report—listed here as the Inspire Veterinary Partners annual report 10-K simplified—to dig into clinic-level margins, debt used to finance acquisitions, and veterinarian staffing costs. Drill further with each Inspire Veterinary Partners 8-K material events explained entry for rapid insight into freshly announced hospital buys or leadership changes. Need executive pay details? The Inspire Veterinary Partners proxy statement executive compensation section highlights them clearly, while AI notes potential alignment risks. And if you monitor ownership shifts, our feed of Inspire Veterinary Partners Form 4 insider transactions real-time flags each purchase or sale, helping you spot buying patterns before earnings season.
Every filing�10-K, 10-Q, 8-K, S-1, or Inspire Veterinary Partners earnings report filing analysis—comes with concise, plain-English explanations that transform legal prose into actionable points. Toggle AI-powered summaries to translate dense accounting language, set alerts for Inspire Veterinary Partners executive stock transactions Form 4, and compare quarter-over-quarter trends without leaving the page. It’s understanding Inspire Veterinary Partners SEC documents with AI—made straightforward, comprehensive, and always up to date.
Lawrence Alexander, a director of Inspire Veterinary Partners, reported acquiring stock options that give the right to purchase 1,447 shares of Class A Common Stock at an exercise price of $17. The options were recorded with a transaction date of 09/26/2024, are exercisable on 09/26/2024 and expire on 09/26/2034, and are held in a direct ownership form.
The filing notes a corporate action that adjusted reported share counts: the issuer effected a 25-to-1 reverse stock split on 01/27/2025, and the numbers on this Form 4 were updated to reflect that split. The report shows 1,447 options outstanding following the transaction, representing the right to buy 1,447 Class A shares at the stated price until 2034.
Frank Richard, Chief Financial Officer of Inspire Veterinary Partners, Inc. (IVP), acquired 58,480 stock options on 04/01/2025. The options carry a $1.71 exercise price, are exercisable on 04/01/2025 and expire 04/01/2035, each covering one Class A common share. The reported ownership is direct. The Form 4 notes the filing was late due to an inadvertent administrative error and is signed 08/06/2025.
Kimball Carr, Chief Executive Officer, President and Chair acquired 92,593 Class A common shares by exercising stock options with a $1.62 exercise (conversion) price on 05/16/2025. The options were exercisable on 05/16/2025 and expire 05/16/2035. Following the reported transaction, 92,593 shares are beneficially owned directly. Remarks state the Form 4 was filed late due to an inadvertent administrative error.
INSPIRE Veterinary Partners officer Kees Lynley acquired 34,247 stock options exercisable immediately on 05/28/2025 with an exercise price of $1.52. Each option converts into one share of Class A Common Stock and the options expire on 05/28/2035. Following the transaction, the reporting person directly beneficially owns 34,247 derivative securities.
Inspire Veterinary Partners (Nasdaq: IVP) filed an 8-K disclosing two capital-raising arrangements that could supply up to $60 million of new funding but introduce meaningful dilution.
On 28-29 Jul 2025 the company signed a Securities Purchase Agreement for a private placement of up to 7,590 Series B convertible preferred shares (stated value $1,000) plus equal-number warrants. At the first closing investors bought 6,340 preferred shares and 6,340,000 five-year warrants for $5 million. The preferred converts at $1.00 per share (floor $0.1876) and the warrants initially exercise at $1.00, both subject to reset on lower-priced issuances. The stock ranks senior to all other equity, has no voting rights, and carries standard anti-dilution, redemption (125% premium) and change-of-control protections. The company must reserve 250 % of the shares needed for conversion and file a resale registration statement.
Separately, IVP entered a $50 million committed equity line with a single accredited investor. IVP may, at its option, sell up to $5 million of common stock per notice when the market price is �$0.75, subject to a 4.99 % ownership cap. Proceeds are earmarked for working capital. Either party can terminate under customary default, delisting or bankruptcy triggers.
- Aggregate potential raise: $60 million
- Immediate cash received: ~$5 million
- Maximum dilution: variable; conversion and warrant floors set at ~$0.19
FAQ
What is the current stock price of INSPIRE VETERINARY PARTNER (IVP)?
What is the market cap of INSPIRE VETERINARY PARTNER (IVP)?
